Contract work opportunities in the biopharma sector have expanded year over year, reflecting a growing preference among employers and professionals for flexible employment arrangements.
Get curated biotech intelligence across AI, industry, innovation, investment, medtech, and policy—delivered to your inbox.
Contract work opportunities in the biopharma sector have expanded year over year, reflecting a growing preference among employers and professionals for flexible employment arrangements.
READ MORE
The Mayo Clinic has entered a health data partnership with Merck to aid in the training of AI systems aimed at enhancing prognosis accuracy, marking an important step in AI application in healthcare.
Novo Nordisk has entered a significant partnership with Vivtex, a biotech startup co-founded by MIT professor Robert Langer, to develop oral medications targeting obesity and diabetes.
Regulators face the complex challenge of balancing safety and access in rare disease treatments, as highlighted by the case of Sarepta Therapeutics’ Elevidys.
LB Pharma navigated a challenging capital market environment in 2025 to secure $350 million for advancing its schizophrenia drug candidate, demonstrating strategic leadership in biotech financing.
Coral Care recently raised $13 million in a Series A funding round to expand its in-home pediatric therapy offerings, supported by a syndicate of notable venture capital firms.
Novo Nordisk has implemented significant price cuts for its obesity drugs, but the effect on patients’ costs and accessibility remains complex.
Slate Medicines has raised $130 million to push forward a promising antibody that targets PACAP, a key protein implicated in migraines.
Cancer drug waste costs healthcare billions annually, but enhanced forecasting techniques offer a promising route to reduce inefficiencies.
Bayer has initiated legal proceedings against Johnson & Johnson, accusing the rival company of conducting a false advertising campaign related to prostate cancer treatments.
Gilead Sciences announced a significant acquisition of Arcellx, a company developing a promising CAR-T cell therapy for multiple myeloma, in a $7.8 billion deal.
